Skip to main content
. 2022 Sep 20;19(19):11877. doi: 10.3390/ijerph191911877

Table 3.

The iron status of the participants of the study (n = 29), accompanied by the other hematological parameters, throughout the study period.

Variables—Baseline Level t0—at Baseline t4—after 4 Weeks of Intervention t8—after 8 Weeks of Intervention p (t0 vs. t4) p (t4 vs. t8) p (t0 vs. t8)
Mean ± SD Median (Min–Max) Mean ± SD Median (Min–Max) Mean ± SD Median (Min–Max)
RBC 4.43 ± 0.34 4.50 (3.60–5.00) 4.50 ± 0.29 4.40 * (4.00–5.20) 4.51 ± 0.32 4.40 (4.00–5.20) 0.0299 0.8191 0.0580
Hb 13.1 ± 0.8 12.9 * (11.0–14.1) 13.3 ± 0.7 13.1 (12.1–14.4) 13.3 ± 0.8 13.3 (11.7–15.4) 0.1059 0.5532 0.0619
Ht 39.7 ± 2.4 40.0 (33.0–43.0) 40.3 ± 1.9 40.0 (37.0–44.0) 40.5 ± 2.3 40.0 (36.0–46.0) 0.0785 0.7262 0.0491
Fe 95.5 ± 45.6 95.6 (24.7–208.8) 85.3 ± 40.1 76.7 * (40.2–217.5) 93.8 ± 50.10 92.8 (25.7–215.1) 0.1919 0.3761 0.8372
SF 36.7 ± 25.8 33.3 * (7.1–119.0) 28.3 ± 22.2 20.8 * (9.1–121.0) 32.8 ± 28.6 29.5 * (7.55–156.0) 0.0128 0.0189 0.3290
MCV 89.8 ± 3.5 90.0 (81.0–95.0) 89.8 ± 4.0 90.0 (81.0–96.0) 89.8 ± 4.0 89.0 (81.0–97.0) 0.9250 1.0000 0.9447
MCH 29.6 ± 1.7 30.0 * (26.0–32.0) 29.5 ± 1.7 30.0 * (26.0–32.0) 29.6 ± 1.7 30.0 * (26.0–32.0) 0.5751 0.4446 0.8139
MCHC 32.9 ± 0.9 32.9 (30.6–34.5) 32.8 ± 0.8 32.9 (31.5–34.3) 32.9 ± 0.8 32.9 (31.4–34.3) 0.5910 0.4608 0.8068
Plt 250.6 ± 63.7 242.0 (42.0–370.0) 255.9 ± 59.7 244.0 (146.0–401.0) 255.2 ± 48.8 257.0 (146.0–344.0) 0.4919 0.9029 0.5386
WBC 6.11 ± 1.50 5.50 * (3.50–9.80) 6.59 ± 2.33 5.90 * (4.10–16.10) 6.11 ± 1.19 5.90 * (3.80–9.00) 0.2106 0.4167 0.3381

* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). RBC—red blood cells (mln/µL); Hb—hemoglobin (g/dL); Ht—hematocrit (%); Fe—serum iron (µg/dL); SF—serum ferritin (ng/mL); MCV—mean corpuscular volume (%); MCH—mean corpuscular hemoglobin (pg); MCHC—mean corpuscular hemoglobin concentration (g/dL); Plt—platelets (109/L); WBC—white blood cells (109/L).